Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMD670 in Charcot-Marie-Tooth disease
NCT06482437Phase 2Completed
- Sponsor
- NMD Pharma
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of ignaseclant in Charcot-Marie-Tooth disease (CMT), sponsored by NMD Pharma. Started Sep 2024; status: completed.
02
Drugs
ignaseclant
03
Conditions
Charcot-Marie-Tooth disease (CMT)
Beyond the preview
Go deeper on NCT06482437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482437.